The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazarovits, A. I.
Right arrow Articles by Stiller, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazarovits, A. I.
Right arrow Articles by Stiller, C. R.

The Journal of Immunology, Vol 150, Issue 11 5163-5174, Copyright © 1993 by American Association of Immunologists

ARTICLES

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection

AI Lazarovits, J Rochon, L Banks, DJ Hollomby, N Muirhead, AM Jevnikar, MJ White, PL Amlot, L Beauregard-Zollinger and CR Stiller
Multi-Organ Transplant Service, University Hospital, London, Ontario, Canada.

mAb directed against CD7 have been shown to inhibit T cell proliferation in the allogeneic mixed lymphocyte reaction suggesting that CD7 may be an appropriate target for in vivo immunotherapy. We performed a prospective randomized clinical trial with a human-mouse chimeric CD7 mAb (SDZCHH380) and compared it with murine OKT3 for the prophylaxis of kidney transplant rejection. Twenty recipients of first cadaveric renal allografts were randomized to receive either SDZCHH380 or OKT3. SDZCHH380 was well tolerated. Rejection was delayed to day 35. No patients were sensitized to SDZCHH380. In contrast 7/10 OKT3 patients made anti-OKT3 antibodies. SDZCHH380 coated peripheral blood and lymph node T cells and, in contrast to OKT3, induced minimal release of IL-2, IL-6, TNF-alpha, and IFN-gamma. In addition, we showed that CD7-negative T cells mediated rejection in one of the SDZCHH380- treated patients. We conclude that the human-mouse chimeric CD7 mAb SDZCHH380 is well tolerated, is not immunogenic, and merits further study in the prophylaxis of transplant rejection.


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
X. M. Mueller
Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants
Ann. Thorac. Surg., January 1, 2004; 77(1): 354 - 362.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. E. Pace, H. P. Hahn, M. Pang, J. T. Nguyen, and L. G. Baum
Cutting Edge: CD7 Delivers a Pro-Apoptotic Signal During Galectin-1-Induced T Cell Death
J. Immunol., September 1, 2000; 165(5): 2331 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. D. Lyman, S. Escobar, A.-M. Rousseau, A. Armstrong, and W. C. Fanslow
Identification of CD7 as a Cognate of the Human K12 (SECTM1) Protein
J. Biol. Chem., February 4, 2000; 275(5): 3431 - 3437.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Z. GAO, R. ZHONG, J. JIANG, B. GARCIA, J. J. XING, M. J. WHITE, and A. I. LAZAROVITS
Adoptively Transferable Tolerance Induced by CD45RB Monoclonal Antibody
J. Am. Soc. Nephrol., February 1, 1999; 10(2): 374 - 381.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.